Search Results

3 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion...
  2. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 022 (also presented at CORESTA SSPT2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); HOENG J.(2); PEITSCH M.(2); SKOWRONEK A.(3); LEE K.M.(1)
    (1) Altria Client Services, Richmond, VA, USA; (2) Philip Morris International, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, USA
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 48

    Six-month systems toxicology inhalation/cessation study in ApoE-/- mice to investigate cardiovascular and respiratory exposure effects of two reduced risk tobacco products compared with conventional cigarettes

    PHILLIPS B.(2); SZOSTAK J.(1); HO J.(2); GUEDJ E.(1); WONG Ee Tsin(2); TALIKKA M.(1); LEBRUN S.(1); TITZ B.(1); MARTIN F.(1); VUILLAUME G.(1); LEROY P.(1); IVANOV N.(1); VANSCHEEUWIJCK P.(1); PEITSCH M.C.(1); HOENG J.(1)
    (1) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (2) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore
    Cigarette smoking causes adverse health effects that may occur shortly after smoking initiation and lead to the development of cardiovascular disease, respiratory disease (chronic obstructive pulmonary disease), and various cancers. To reduce the...